Bahman Jabbari

Prof. Bahman Jabbari

Department of Neurology, Yale University School of Medicine, New Haven, CT 06519, USA
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2016 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
RRRezvan Rostami
Rezvan Rostami
SMShivam Om Mittal
Shivam Om Mittal
PRPooya Rostami
Pooya Rostami
FTFattaneh Tavassoli
Fattaneh Tavassoli
Bahman JabbariBahman Jabbari
Bahman Jabbari

21 May 2013 in Toxins
Verified
Journal Article
Open access
PDF file
ALAmanda Amrita Lakraj
Amanda Amrita Lakraj
NMNarges Moghimi
Narges Moghimi
Bahman JabbariBahman Jabbari
Bahman Jabbari
Sialorrhea or excessive drooling is a major issue in children with cerebral palsy and adults with neurodegenerative disorders. In this review, we describe the clinical features, anatomy and physiology of sialorrhea, as well as a review of the world literature on medical treatment using Yale University’s search engine; including but not limited to Medline and Erasmus. Level of drug efficacy is defined according to the guidelines of American Academy of Neurology. Current medical management is unsatisfactory. Topical agents (scopolamine and tropicamide) and oral agents (glyccopyrolate) combined render a level B evidence (probably effective); however, this treatment is associated with troublesome side effects. Double-blind and placebo-controlled studies of botulinum toxin (BoNT) provide a level A evidence for type B (two class I studies; effective and established) and both overall and individual B level of evidence for OnabotulinumtoxinA (A/Ona) and AbobotulinumtoxinA (A/Abo); these are probably effective. For IncobotulinumtoxinA (A/Inco), the level of evidence is U (insufficient) due to lack of blinded studies. Side effects are uncommon; transient and comparable between the two types of toxin. A clinical note at the end of this review comments on fine clinical points. Administration of BoNTs into salivary glands is currently the most effective way of treating sialorrhea.

1 June 2018 in Toxicon
Verified
Journal Article
Closed access
YSYasaman Safarpour
Yasaman Safarpour
Bahman JabbariBahman Jabbari
Bahman Jabbari

23 April 2013 in Toxins
Verified
Journal Article
Open access
PDF file
ALAmanda-Amrita D. Lakraj
Amanda-Amrita D. Lakraj
NMNarges Moghimi
Narges Moghimi
Bahman JabbariBahman Jabbari
Bahman Jabbari
Clinical features, anatomy and physiology of hyperhidrosis are presented with a review of the world literature on treatment. Level of drug efficacy is defined according to the guidelines of the American Academy of Neurology. Topical agents (glycopyrrolate and methylsulfate) are evidence level B (probably effective). Oral agents (oxybutynin and methantheline bromide) are also level B. In a total of 831 patients, 1 class I and 2 class II blinded studies showed level B efficacy of OnabotulinumtoxinA (A/Ona), while 1 class I and 1 class II study also demonstrated level B efficacy of AbobotulinumtoxinA (A/Abo) in axillary hyperhidrosis (AH), collectively depicting Level A evidence (established) for botulinumtoxinA (BoNT-A). In a comparator study, A/Ona and A/Inco toxins demonstrated comparable efficacy in AH. For IncobotulinumtoxinA (A/Inco) no placebo controlled studies exist; thus, efficacy is Level C (possibly effective) based solely on the aforementioned class II comparator study. For RimabotulinumtoxinB (B/Rima), one class III study has suggested Level U efficacy (insufficient data). In palmar hyperhidrosis (PH), there are 3 class II studies for A/Ona and 2 for A/Abo (individually and collectively level B for BoNT-A) and no blinded study for A/Inco (level U). For B/Rima the level of evidence is C (possibly effective) based on 1 class II study. Botulinum toxins (BoNT) provide a long lasting effect of 3–9 months after one injection session. Studies on BoNT-A iontophoresis are emerging (2 class II studies; level B); however, data on duration and frequency of application is inconsistent.

11 August 2017 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
Bahman JabbariBahman Jabbari
Bahman Jabbari
NVNosratola D. Vaziri
Nosratola D. Vaziri

1 November 2011 in Pain Medicine
Verified
Journal Article
Closed access
PDF file
Bahman JabbariBahman Jabbari
Bahman Jabbari
DMDuarte Machado
Duarte Machado